These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 27812962)
41. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. Staels B Am J Cardiol; 2017 Jul; 120(1S):S28-S36. PubMed ID: 28606341 [TBL] [Abstract][Full Text] [Related]
42. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Scheen AJ Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129 [TBL] [Abstract][Full Text] [Related]
43. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602 [TBL] [Abstract][Full Text] [Related]
45. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE; N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978 [TBL] [Abstract][Full Text] [Related]
46. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118 [TBL] [Abstract][Full Text] [Related]
47. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Bonadonna RC; Borghi C; Consoli A; Volpe M Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139 [TBL] [Abstract][Full Text] [Related]
48. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence. White JR Ann Pharmacother; 2015 May; 49(5):582-98. PubMed ID: 25712444 [TBL] [Abstract][Full Text] [Related]
49. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Sattar N; McLaren J; Kristensen SL; Preiss D; McMurray JJ Diabetologia; 2016 Jul; 59(7):1333-1339. PubMed ID: 27112340 [TBL] [Abstract][Full Text] [Related]
50. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360 [TBL] [Abstract][Full Text] [Related]
51. Empagliflozin for the treatment of Type 2 diabetes. Gangadharan Komala M; Mather A Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752 [TBL] [Abstract][Full Text] [Related]
52. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B; Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445 [TBL] [Abstract][Full Text] [Related]
53. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related]
54. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE; Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355 [TBL] [Abstract][Full Text] [Related]
55. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Ferrannini E; Mark M; Mayoux E Diabetes Care; 2016 Jul; 39(7):1108-14. PubMed ID: 27289126 [TBL] [Abstract][Full Text] [Related]
57. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality. Arbel R; Hammerman A; Azuri J Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890 [TBL] [Abstract][Full Text] [Related]
58. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality]. Zechmann S Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688 [No Abstract] [Full Text] [Related]
59. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Kaul S Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887 [TBL] [Abstract][Full Text] [Related]
60. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]